KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBT Margin (2017 - 2025)

Sarepta Therapeutics (SRPT) has 12 years of EBT Margin data on record, last reported at 25.14% in Q2 2025.

  • For Q2 2025, EBT Margin rose 2138.0% year-over-year to 25.14%; the TTM value through Jun 2025 reached 35.97%, up 1209.0%, while the annual FY2024 figure was 147.93%, 17056.0% up from the prior year.
  • EBT Margin reached 25.14% in Q2 2025 per SRPT's latest filing, up from 7.69% in the prior quarter.
  • Across five years, EBT Margin topped out at 199.35% in Q4 2022 and bottomed at 1139.89% in Q3 2022.
  • Average EBT Margin over 5 years is 98.37%, with a median of 20.5% recorded in 2021.
  • Peak YoY movement for EBT Margin: tumbled -111939bps in 2022, then soared 99242bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 108.85% in 2021, then skyrocketed by 283bps to 199.35% in 2022, then crashed by -70bps to 60.2% in 2023, then tumbled by -113bps to 7.69% in 2024, then soared by 427bps to 25.14% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 25.14% in Q2 2025, 7.69% in Q4 2024, and 3.11% in Q3 2024.